Isabel M. Heidegger

Innsbruck, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 184 publications

Function drives 1-year decision regret in radical prostatectomy: a multicentre prospective study.

Function drives 1-year decision regret in radical prostatectomy: a multicentre prospective study.

Journal: BJU international

Published: July 10, 2026

Personalized therapy in metastatic hormone-sensitive prostate cancer: a 2026 update on navigating therapeutic complexity.

Personalized therapy in metastatic hormone-sensitive prostate cancer: a 2026 update on navigating therapeutic complexity.

Journal: Current opinion in urology

Published: July 04, 2026

Re: Luka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al. IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.014.

Re: Luka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al. IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.014.

Journal: European urology

Published: June 17, 2026

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

Journal: European urology oncology

Published: June 03, 2026

Prospective validation of a urine-based proteomics test for predicting clinically significant prostate cancer in biopsy-naïve patients.

Prospective validation of a urine-based proteomics test for predicting clinically significant prostate cancer in biopsy-naïve patients.

Journal: British journal of cancer

Published: March 13, 2026

Therapy-Associated Neuroendocrine Prostate Cancer (tNEPC): A Diagnostic and Therapeutic Challenge in Uro-Oncology with Emerging Clinical Implications

Therapy-Associated Neuroendocrine Prostate Cancer (tNEPC): A Diagnostic and Therapeutic Challenge in Uro-Oncology with Emerging Clinical Implications

Journal: Aktuelle Urologie

Published: January 22, 2026

Real-World Use of Prolaris® to Guide Treatment Decisions in Localized Prostate Cancer Eligible for Active Surveillance.

Real-World Use of Prolaris® to Guide Treatment Decisions in Localized Prostate Cancer Eligible for Active Surveillance.

Journal: Urologia internationalis

Published: January 21, 2026

Treatment options in rare urological tumors: potential of molecular tumor boards

Treatment options in rare urological tumors: potential of molecular tumor boards

Journal: Urologie (Heidelberg, Germany)

Published: December 08, 2025

Impact of Negative Prostate-specific Membrane Antigen Positron Emission Tomography on the Decision to Perform a Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- to High-risk Prostate Cancer Patients: Results of an International Survey.

Impact of Negative Prostate-specific Membrane Antigen Positron Emission Tomography on the Decision to Perform a Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- to High-risk Prostate Cancer Patients: Results of an International Survey.

Journal: European urology open science

Published: December 05, 2025

Integration of Darolutamide in the Treatment Landscape for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis of Efficacy and Safety.

Integration of Darolutamide in the Treatment Landscape for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis of Efficacy and Safety.

Journal: European urology open science

Published: November 21, 2025

Real-world monitoring strategies and predictors guiding the transition from active surveillance to treatment in ISUP 1 prostate cancer.

Real-world monitoring strategies and predictors guiding the transition from active surveillance to treatment in ISUP 1 prostate cancer.

Journal: Journal of cancer research and clinical oncology

Published: September 22, 2025

Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study.

Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study.

Journal: Urologic oncology

Published: September 21, 2025

Showing 1-12 of 184

Last Updated: 09/26/2026